Daiichi Sankyo
Jennifer Adeleye currently serves as the Director of Clinical Science in Oncology at Daiichi Sankyo, Inc. since September 2023. Previously, Jennifer held the position of Director, Clinical Scientist at G1 Therapeutics, Inc. from 2021 to September 2023, and worked as Associate Director, Clinical Scientist at ADC Therapeutics from 2019 to 2021. Jennifer's experience includes serving as a Clinical Scientist in Oncology at ExecuPharm/Merck and managing alliance relationships at Yale School of Medicine between 2015 and 2018, where coordination of Phase I clinical trials was also a key role. Prior academic endeavors include a PhD in Cancer Biology from Gerstner Sloan Kettering Graduate School and involvement in research at Memorial Sloan-Kettering Cancer Center and Harvard Medical School. Educational background includes a BA in Chemistry from California State University, Northridge.
This person is not in any teams
This person is not in any offices
Daiichi Sankyo
21 followers
Daiichi Sankyo Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical products. It operates through the following segments: Daiichi Sankyo Group and Ranbaxy Group. The Daiichi Sankyo Group segment comprises of Daiichi Sankyo Co., Ltd. and its subsidiaries. The Ranbaxy Group segment includes its core company, Ranbaxy Laboratories Ltd. Both group segments deal with business activities in prescription drugs and general pharmaceutical products. The company was founded on September 28, 2005 and is headquartered in Tokyo, Japan.